middle.news
AdAlta strengthens EW-001's US pathway with orphan designation
8:28am on Tuesday 17th of November, 2026 AEDT
•
Biotechnology
Read Story
AdAlta strengthens EW-001's US pathway with orphan designation
8:28am on Tuesday 17th of November, 2026 AEDT
Key Points
US orphan designation assigned to AdAlta by Shanghai Cell Therapy Group
Potential seven-year US exclusivity applies only if EW-001 is approved
FDA pre-IND meeting supported using data from multiple manufacturing variants
Australian manufacturing run scheduled for December 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE